Detection of HER2 through Antibody Immobilization Is Influenced by the Properties of the Magnetite Nanoparticle Coating

被引:7
|
作者
Villegas-Serralta, Enrique [1 ]
Zavala, Oscar [2 ]
Alejandro Flores-Urquizo, Israel [3 ]
Garcia-Casillas, Perla E. [1 ]
Chapa Gonzalez, Christian [1 ]
机构
[1] Univ Autonoma Ciudad Juarez, Inst Ingn & Tecnol, Ciudad Juarez, Chih, Mexico
[2] Univ Autonoma Ciudad Juarez, Inst Ciencias Biomed, Ciudad Juarez, Chih, Mexico
[3] Univ Autonoma Nuevo Leon, Fac Ciencias Quim, San Nicolas De Los Garza, NL, Mexico
关键词
BREAST-CANCER; ALBUMIN;
D O I
10.1155/2018/7571613
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Considerable effort has been focused on improving the control of size, shape, and surface modifications to detect proteins. The purpose of this study was to compare the efficiencies of aminosilane-coated magnetite (As-M) nanoparticles (NPs), dextran-coated magnetite nanoparticles (Dx-M), and bare nanoparticles for conjugating single-chain variable fragment antibodies (scFvs) with the aim of detecting the human epidermal growth factor receptor 2 (HER2) protein. Dx-M and As-M NPs were characterized using scanning electron microscopy, energy dispersive X-ray spectroscopy, X-ray diffraction, and Raman spectroscopy. Dx-M and As-M were conjugated with a monoclonal scFv for active targeting of the HER2 antigen. Aminosilane surface coating enhanced the scFv conjugation efficiency over twofold compared to that of the dextran-coated magnetite NPs for the detection of HER2 proteins.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] An Electrochemical Sandwich Immunosensor for the Detection of HER2 using Antibody-Conjugated PbS Quantum Dot as a label
    Lah, Zur Mira Azizah Nor Haiza
    Ahmad, Shahrul Ainliah Alang
    Zaini, Muhammad Safwan
    Kamarudin, Mazliana Ahmad
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 174 : 608 - 617
  • [42] Performance of AmoyDx HER2 mutation detection kit and AmoyDx Pan Lung Cancer PCR Panel for detection of common HER2 and/or EGFR mutations
    Sheng, M.
    Brown, H.
    Dearden, S.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S334 - S334
  • [43] Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
    Yu, Xiaojie
    Wang, Lingfei
    Shen, Yafeng
    Wang, Chao
    Zhang, Yajun
    Meng, Yanchun
    Yang, Yang
    Liang, Beibei
    Zhou, Bo
    Wang, Huajing
    Wei, Huafeng
    Lei, Changhai
    Hu, Shi
    Li, Bohua
    MOLECULAR IMMUNOLOGY, 2017, 87 : 300 - 307
  • [44] Long term survival of metastatic HER2 positive breast cancer patients with no radiographic evidence of disease (NED) on HER2 antibody therapy
    Bennett, Alexis
    Chen, Zhengyi
    Martin, James
    Mallat, Naji
    Fu, Pingfu
    Montero, Alberto
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Anti HER2 rabbit monoclonal antibody SP3 is a better predictor of HER2 gene status in invasive breast carcinoma
    Orvieto, E.
    Zanatta, L.
    Rossi, S.
    Furlanetto, A.
    Canal, F.
    Laurino, L.
    Dei Tos, A. P.
    MODERN PATHOLOGY, 2007, 20 : 44A - 44A
  • [46] Comparison between the Bond Oracle HER2 immunohistochemical system, the polyclonal HER2 Dako antibody and Chromogenic In Situ Hybridization in breast carcinoma
    Kourea, H.
    Tzelepi, V.
    Nikolatou, I.
    Ravazoula, P.
    Zolota, V.
    VIRCHOWS ARCHIV, 2012, 461 : S244 - S245
  • [47] HER2 ASSESSMENT ON CORE BIOPSIES USING MONOCLONAL ANTIBODY CB11 ACCURATELY DETERMINES HER2 STATUS IN BREAST CARCINOMA
    Purdie, C. A.
    Jordan, L.
    McCullough, J.
    Edwards, S.
    Cunningham, J.
    Grant, A.
    Pratt, N.
    Thompson, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 38 - 38
  • [48] Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells.
    Woods, Richard
    Brack, Simon
    Klupsch, Kristina
    Wuellner, Ulrich
    Buller, Fabian
    Santimaria, Roger
    Attinger-Toller, Isabella
    Koenig-Friedrich, Susann
    Zbinden, Irene
    Bertschinger-Ehrler, Julian
    Grabulovski, Dragon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Anti HER2 rabbit monoclonal antibody SP3 is a better predictor of HER2 gene status in invasive breast carcinoma
    Orvieto, E.
    Zanatta, L.
    Rossi, S.
    Furlanetto, A.
    Canal, F.
    Laurino, L.
    Dei Tos, A. P.
    LABORATORY INVESTIGATION, 2007, 87 : 44A - 44A
  • [50] Increased CD4 T Cell and Antibody Responses by Addition of Recombinant HER2 Protein to MVA-BN®-HER2
    Mandl, Stefanie J.
    Rountree, Ryan B.
    Cote, Joseph
    dela Cruz, Tracy
    Giffon, Thierry
    Lombardo, John R.
    Trent, Erica
    Laus, Reiner
    Delcayre, Alain
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 772 - 772